Why choose Organoid Technology for your ADC program?
Traditional ADC models like 2D cell lines and PDXs often fail to predict clinical outcomes, leading to high attrition and dose-limiting toxicities. Patient-derived organoids (PDOs) provide a more predictive alternative. These 3D tumor models preserve patient-specific architecture and genetics, enabling accurate assessment of ADC efficacy and off-target toxicities across both tumor and healthy tissues.
What you'll learn:
- How patient-derived organoids (PDOs) outperform traditional cell lines and PDX models in ADC development
- Data showcasing how HUB Organoids capture the diversity of patient responses
- An overview of our comprehensive ADC services portfolio
- Two in-depth case studies illustrating how we’ve helped clients make confident, data-driven preclinical decisions
Discover our ADC development solutions
Whether you need to assess antigen expression in patient-derived models, evaluate ADC potency and off-target toxicities, or run basket screens across multiple cancer indications, our tailored service packages are designed to accelerate your program.
